Vistagen Therapeutics, Inc.: Form 10-Q for the period ended Dec 31, 2015
Filed with the SEC on Feb 16, 2016 and accepted by EDGAR at Feb 16, 2016, 16:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Operating income | 3 months2015-10-01 to 2015-12-31 | −$2.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2015-04-01 to 2015-12-31 | −$9.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2015-10-01 to 2015-12-31 | $2.5k | us-gaap:InterestExpense |
| Interest expense | 9 months2015-04-01 to 2015-12-31 | $769.8k | us-gaap:InterestExpense |
| Income tax | 9 months2015-04-01 to 2015-12-31 | $2.3k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2015-10-01 to 2015-12-31 | −$2.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months2015-04-01 to 2015-12-31 | −$38.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2015-10-01 to 2015-12-31 | −$1.95 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2015-04-01 to 2015-12-31 | −$25.45 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2015-10-01 to 2015-12-31 | −$1.95 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2015-04-01 to 2015-12-31 | −$25.45 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2015-10-01 to 2015-12-31 | 1,765,641 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2015-04-01 to 2015-12-31 | 1,650,160 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2015-04-01 to 2015-12-31 | −$3.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2015-12-31 | $1.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2015-12-31 | $1.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2015-12-31 | $2.0m | us-gaap:Assets |
| Current liabilities | At period end2015-12-31 | $2.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2015-12-31 | $3.6m | us-gaap:Liabilities |
| Long-term debt | At period end2015-12-31 | $29.3k | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2015-12-31 | −$1.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001415889-16-004781. Last ingested by Listed: Oct 30, 2026, 17:32 ET. Listed shows no prices and gives no investment advice.